Allmed Medical Products Co., Ltd (002950.SZ)
CNY 8.48
(0.12%)
CNY 8.48
(0.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 409.86 Million CNY | -47.73% |
| 2022 | 696.67 Million CNY | 16.62% |
| 2021 | 672.87 Million CNY | -53.88% |
| 2020 | 1.49 Billion CNY | 159.48% |
| 2019 | 558.4 Million CNY | 32.7% |
| 2018 | 427.58 Million CNY | 6.86% |
| 2017 | 394.54 Million CNY | 1.56% |
| 2016 | 391.2 Million CNY | 34.45% |
| 2015 | 283.98 Million CNY | -20.74% |
| 2014 | 321.84 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 176.16 Million CNY | 6.9% |
| 2024 Q3 | 105.24 Million CNY | -46.61% |
| 2024 Q1 | 127.7 Million CNY | 526.06% |
| 2023 Q3 | 16.38 Million CNY | -76.06% |
| 2023 Q2 | 68.43 Million CNY | -34.69% |
| 2023 Q1 | 104.79 Million CNY | -34.44% |
| 2023 FY | - CNY | -47.73% |
| 2023 Q4 | 25.67 Million CNY | 56.67% |
| 2022 Q2 | 211.31 Million CNY | 8.99% |
| 2022 FY | - CNY | 16.62% |
| 2022 Q4 | 159.86 Million CNY | 517.2% |
| 2022 Q3 | 25.9 Million CNY | -87.74% |
| 2022 Q1 | 193.88 Million CNY | 70.81% |
| 2021 Q2 | 142.02 Million CNY | -10.8% |
| 2021 Q1 | 159.22 Million CNY | -24.06% |
| 2021 FY | - CNY | -53.88% |
| 2021 Q4 | 113.5 Million CNY | 2.8% |
| 2021 Q3 | 110.41 Million CNY | -22.26% |
| 2020 FY | - CNY | 159.48% |
| 2020 Q2 | 705.23 Million CNY | 437.09% |
| 2020 Q4 | 209.68 Million CNY | -22.14% |
| 2020 Q1 | 131.3 Million CNY | 25.16% |
| 2020 Q3 | 269.3 Million CNY | -61.81% |
| 2019 Q4 | 104.91 Million CNY | -34.52% |
| 2019 Q2 | 101.78 Million CNY | 38.46% |
| 2019 Q1 | 73.51 Million CNY | -46.14% |
| 2019 FY | - CNY | 32.7% |
| 2019 Q3 | 160.22 Million CNY | 57.41% |
| 2018 Q4 | 136.48 Million CNY | 25.01% |
| 2018 Q2 | 65.29 Million CNY | 10.67% |
| 2018 Q1 | 58.99 Million CNY | 22180.39% |
| 2018 FY | - CNY | 6.86% |
| 2018 Q3 | 109.17 Million CNY | 67.2% |
| 2017 Q4 | -267.2 Thousand CNY | 0.0% |
| 2017 FY | - CNY | 1.56% |
| 2016 FY | - CNY | 34.45% |
| 2015 FY | - CNY | -20.74% |
| 2014 FY | - CNY | 0.0% |